ATAI | LIFE SCIENCES
310
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-310,,qode-page-loading-effect-enabled,qode-title-hidden,qode_grid_1300,qode-child-theme-ver-1.0.0,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.6,vc_responsive

The biotech platform
to ultimately cure aging and
mental health disorders.

About us

Leveraging cutting-edge
scientific research and technology

ATAI Life Sciences AG is a global biotech company builder. Our mission is to enable people to live longer, healthier and happier lives.

We envisage an end to aging and mental health disorders. We believe in living to 100 years old and beyond, but healthily and happily. Our initial focus is on developing solutions for the 320 million people who suffer from depression, a significant unmet medical need.

We take a decentralized and data-driven platform approach that leverages artificial intelligence, financial resources and access to talent, to give innovative compounds the support and kick-start they need to be successful.

We acquire compounds, usually at an early stage of the drug development process, that can benefit from being incubated on our platform. Our decentralized and lean setup allows us to spread knowledge, learning and best practice across the ATAI platform, accelerating the pace at which drug compounds can move through early stage clinical trials.

We are rethinking the drug development process, and are confident that technology will play a critical role in reducing time and cost in the development of mental health and longevity therapies.

Focus on
Mental health

ATAI is supporting the revival of psychedelic compounds, such as psilocybin and ketamine, in the treatment of mental health conditions

Focus on
Longevity

ATAI is looking into different ways to increase the human healthspan and reverse aging

Focus on
AI & Big Data

ATAI is leveraging the potential of artificial intelligence (AI) and big data analytics to optimize and accelerate the drug development process

Our Strategy

The evolution of biotech
Science fiction becomes reality

Technology has kicked off a new era of biotech, outpacing Moore’s law. We acquire compounds that can benefit from leveraging this technological advancement by developing them on our platform. Compounds that we acquire are in general at an early stage of the drug development process.

We envision to put an end to aging and mental health disorders. To deliver on this vision, we initially focus on developing solutions for people that suffer from a real unmet medical need – starting with the 320mn patients that suffer from depression.

We believe that small teams are more effective and efficient. Our decentralized and lean setup allows us to constantly spread learning, expertise and best practices across the ATAI platform enabling operational excellence and entrepreneurship.

World-class business and science experts ensure successful execution of acquisitions and pre-clinical & clinical studies in record speed.

Our Team

Vast experience
and great access to deal flow

Christian Angermayer

Founder

Lars Wilde

Co-founder

Florian Brand

Co-founder and CEO

Simon Seibold

Associate

Philipp Schreiber

Associate

Our Companies

A portfolio of innovation
Accelerating progress in life sciences

COMPASS Pathways

develops psilocybin therapy for patients with treatment-resistant depression.
compasspathways.com

Perception Neuroscience

develops arketamine therapy for patients with neuropsychiatric diseases.
perceptionneuroscience.com

Innoplexus

leverages the power of AI and big data analytics for a variety of applications in life sciences, like drug development.
innoplexus.com

Juvenescence

invests in companies with therapies for aging and age-related diseases.
juvenescence.ltd

Insights

Learn about cutting-edge science
and gain life-enhancing insights

Follow us on Twitter and read our blog

Careers

Work with us
to improve the lives of millions of people

WE ARE HIRING! Learn about career opportunities at ATAI and see open jobs across our platform companies.

Let’s stay in touch

Sign up to our newsletter to receive updates on our progress:

75%

A biography (or simply bio) is a detailed description of a person’s life. It involves more than just the basic facts like education, work, relationships.

43%

A biography (or simply bio) is a detailed description of a person’s life. It involves more than just the basic facts like education, work, relationships.

87%

A biography (or simply bio) is a detailed description of a person’s life. It involves more than just the basic facts like education, work, relationships.

ATAI is looking into different ways to increase the human healthspan and reverse aging

Technological advances in areas like genomics, stem cell therapy, immunology and nanotechnology will change how we age.

We believe that

Christian Angermayer

Founder

Strategy and investor relations

Lars Wilde

Co-founder

Drug discovery and compound sourcing

Florian Brand

Co-founder and CEO

Drug development and operations

Simon Seibold

Associate

Investments and business development

Philipp Schreiber

Associate

Drug discovery and compound sourcing

ATAI is supporting the revival of psychedelic compounds, such as psilocybin and ketamine, in the treatment of mental health conditions

Depression, anxiety, post-traumatic stress disorder, obsessive-compulsive disorder, bipolar disorder and other psychiatric conditions are increasingly becoming a burden for patients, families and societies.

We believe that

ATAI is leveraging the potential of artificial intelligence (AI) and big data analytics to optimize and accelerate the drug development process

Technological innovation will enable us to consolidate and make sense of vast amounts of previously inaccessible data.

We believe that

Sorry,

there are no positions available at this time.

Please check back soon.